Neurocrine Biosciences
Clinical trials sponsored by Neurocrine Biosciences, explained in plain language.
-
SCN8A seizure drug study halted early
Disease control TerminatedThis study tested an experimental drug called NBI-921352 in people aged 2 to 21 with a rare genetic epilepsy (SCN8A-DEE). The goal was to see if adding this drug to their current seizure medicines could reduce seizure frequency. The study was terminated early, so results are limi…
Phase: PHASE2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Experimental epilepsy drug tested for long-term safety in children with rare sleep disorder
Symptom relief TerminatedThis study looked at the long-term safety of an experimental drug called NBI-827104 in children with a rare form of epilepsy that causes continuous brain activity during sleep. The study enrolled 19 children and was terminated early. The main goal was to track serious side effect…
Phase: PHASE2 • Sponsor: Neurocrine Biosciences • Aim: Symptom relief
Last updated May 17, 2026 02:00 UTC